Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Medicine and Dentistry New Jersey AVVAA World Healthcare Products, Inc. |
---|---|
Information provided by: | University of Medicine and Dentistry New Jersey |
ClinicalTrials.gov Identifier: | NCT00143819 |
The purpose of this study is to assess the efficacy of Neuroskin Forte in relieving the symptoms of dry skin in adults with psoriasis or eczema.
Condition | Intervention | Phase |
---|---|---|
Psoriasis Eczema |
Drug: Neuroskin Forte Drug: Placebo Application |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment |
Official Title: | Double-Blind, Bilateral, Vehicle-Controlled, Randomized Trial of Neuroskin Forte to Relieve Symptoms of Dry Skin |
Estimated Enrollment: | 40 |
Study Start Date: | September 2005 |
Estimated Study Completion Date: | December 2007 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
bilateral comparison
|
Drug: Neuroskin Forte
Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
|
2: Placebo Comparator
bilateral comparison
|
Drug: Placebo Application
Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
|
Subjects will apply study drug and placebo sprays 3 times a day to the assigned, randomized sides of the body. They are allowed to continue using prescription medications, but not moisturizers. Assessments will be performed every other week. Total duration of the study is 10 weeks (8 weeks of treatment and a follow-up visit 2 weeks later).
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Contact: Irina Lipets, RN, BSN | 732-235-5737 | lipetsir@umdnj.edu |
United States, New Jersey | |
UMDNJ Division of Clinical Pharmacology | Recruiting |
New Brunswick, New Jersey, United States, 08901 | |
Contact: Patricia Hanas 732-235-8063 hanaspw@umdnj.edu |
Principal Investigator: | Melissa Magliocco, MD | University of Medicine and Dentistry New Jersey |
Responsible Party: | UMDNJ-RWJMS ( Melissa Magliocco, MD ) |
Study ID Numbers: | 5494 |
Study First Received: | August 31, 2005 |
Last Updated: | October 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00143819 |
Health Authority: | United States: Institutional Review Board |
psoriasis dry skin eczema atopic dermatitis |
Dermatitis, Atopic Skin Diseases Psoriasis Skin Diseases, Eczematous |
Eczema Skin Diseases, Papulosquamous Dermatitis |